Overview

### Bio
Dr. Mark Wilke is a partner based out of Vancouver, Canada, practising in the firm's global Intellectual Property and Life Sciences groups.
His practice focuses on international patent prosecution and strategic patent portfolio counseling across a broad range of industries, including pharmaceuticals, biotechnology, agriculture, and cleantech, with an emphasis on patenting innovative technologies in the areas of molecular biology, immunology, biochemistry, chemistry, chemical engineering, and medical devices.
Prior to his legal career, Mark completed a doctorate at the University of British Columbia, where he investigated the regulation of antibiotic resistance in pathogenic superbugs using X-ray crystallography and nuclear magnetic resonance.
Mark is a registered patent agent in both Canada and the United States.
**Scam Warning**
Have you received an email bearing my name, but originating from an email address other than @gowlingwlg.com? Does it suggest urgent action needs to be taken to preserve your trademark rights?
**It is not from me and not legitimate.**
[Read more in this advisory](https://cpata-cabamc.ca/en/trademark-scam-circulating-cpata-advises-public-caution/ "") from the College of Patent and Trademark Agents.
### Career & education
#### Career highlights
2013
Patent Agent, Canada
2013
Patent Agent, USA
2013
Trademark Agent, Canada
#### Education
2011
University of British Columbia, JD
2008
University of British Columbia, PhD, Biochemistry
2002
University of Guelph, B.Sc., Biochemistry
#### Languages
English
##### Memberships
- Canadian Bar Association
- Intellectual Property Institute of Canada (IPIC)
### Publications & speaking engagements
Wilke, MS *et al.*, "Patenting across three jurisdictions", Intellectual Property Magazine, April 2020, pages 37-38.
Wilke MS, Prohibiting Medical Method Patents: A Criticism of the Status Quo, 2011, C.J.L.T. 9(2), 2009.
Wilke MS, Heller M, Creagh L, Haynes C, McIntosh L, Poole K, Strynadka NC (2008) The crystal structure of MexR from Pseudomonas aeruginosa in complex with its anti-repressor ArmR. Proc Natl Acad Sci USA 105, 14832-37.
Daigle DM, Cao L, Fraud S, Wilke MS, Pacey A, Klinoski R, Strynadka NC, Dean CR, and Poole K. (2007) A Protein Modulator of Multidrug Efflux Gene Expression in Pseudomonas aeruginosa. J Bacteriol 189, 5441-51.
Wilke MS, Lovering AL, Strynadka NC (2005) Beta-lactam antibiotic resistance: a current structural perspective. Curr Opin Microbiol 8, 525-33.
Wilke MS, Hills TL, Zhang HZ, Chambers HF, Strynadka NC (2004) Crystal structures of the apo and penicillin-acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus. J Biol Chem 279, 47278-87.
Bateman KP, Baker J, Wilke M, Lee J, Leriche T, Seto C, Day S, et al. (2004) Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry. Chem Res Toxicol 17, 1356-61.

Practice Areas

• Intellectual Property

Bar Information

Called to the bar: 2012 (BC)

Professional Details